MeSH term
Frequency | Condition_Probility | Adult | 49 | 0.0 |
Comparative Study | 33 | 0.0 |
Humans | 288 | 0.0 |
Acrocephalosyndactylia/*genetics/pathology | 2 | 66.0 |
Child, Preschool | 25 | 0.0 |
DNA/chemistry/genetics | 3 | 0.0 |
DNA Mutational Analysis | 30 | 0.0 |
Family Health | 4 | 0.0 |
Female | 107 | 0.0 |
In Situ Hybridization, Fluorescence | 17 | 0.0 |
Infant | 21 | 0.0 |
Karyotyping | 5 | 0.0 |
Male | 97 | 0.0 |
Mutation, Missense | 4 | 0.0 |
*Nuclear Proteins | 5 | 0.0 |
Pedigree | 31 | 0.0 |
Phenotype | 41 | 0.0 |
*Protein-Tyrosine Kinase | 173 | 57.0 |
Receptors, Fibroblast Growth Factor/genetics | 31 | 46.0 |
Research Support, Non-U.S. Gov't | 195 | 0.0 |
Transcription Factors/genetics | 7 | 0.0 |
Arginine/genetics | 4 | 2.0 |
Cysteine/genetics | 5 | 4.0 |
English Abstract | 14 | 0.0 |
Fatal Outcome | 2 | 0.0 |
Infant, Newborn | 19 | 0.0 |
Point Mutation/genetics | 3 | 1.0 |
Receptors, Fibroblast Growth Factor/genetics/metabolism | 5 | 21.0 |
Antibodies/diagnostic use | 2 | 4.0 |
Biological Markers/analysis | 2 | 0.0 |
Cell Differentiation | 16 | 0.0 |
Cytoplasm/ultrastructure | 2 | 3.0 |
Dyes/diagnostic use | 2 | 2.0 |
Epithelium/pathology | 2 | 1.0 |
Fibroblast Growth Factor 1/*analysis | 2 | 40.0 |
Fibroblast Growth Factor 2/*analysis | 3 | 15.0 |
Immunohistochemistry | 20 | 0.0 |
Receptor Protein-Tyrosine Kinases/*analysis | 2 | 4.0 |
Receptors, Fibroblast Growth Factor/*analysis | 4 | 44.0 |
Aged | 30 | 0.0 |
DNA, Neoplasm/analysis | 3 | 0.0 |
Fibroblast Growth Factors/metabolism | 11 | 21.0 |
Gene Expression Profiling | 4 | 0.0 |
Middle Aged | 37 | 0.0 |
Neoplasm Proteins/*genetics | 2 | 0.0 |
Oligonucleotide Array Sequence Analysis | 6 | 0.0 |
Poly A/metabolism | 2 | 4.0 |
Proto-Oncogene Proteins/metabolism | 4 | 0.0 |
RNA, Messenger/metabolism | 6 | 0.0 |
Time Factors | 5 | 0.0 |
Up-Regulation | 4 | 0.0 |
Achondroplasia/*genetics | 26 | 83.0 |
Point Mutation | 25 | 1.0 |
Polymorphism, Restriction Fragment Length | 7 | 0.0 |
Polymorphism, Single-Stranded Conformational | 13 | 0.0 |
Receptors, Fibroblast Growth Factor/*genetics | 117 | 51.0 |
Animals | 96 | 0.0 |
Cell Transformation, Neoplastic | 5 | 0.0 |
Gene Expression Regulation, Neoplastic | 12 | 0.0 |
Mutation | 34 | 0.0 |
Receptors, Fibroblast Growth Factor/*metabolism | 10 | 18.0 |
Research Support, U.S. Gov't, P.H.S. | 85 | 0.0 |
Translocation, Genetic | 9 | 1.0 |
Apoptosis/genetics | 2 | 0.0 |
DNA-Binding Proteins/genetics | 6 | 0.0 |
Exons/genetics | 7 | 0.0 |
Fibroblast Growth Factor 2/genetics | 2 | 6.0 |
Fibroblast Growth Factors/*genetics | 11 | 22.0 |
Image Processing, Computer-Assisted | 2 | 0.0 |
In Situ Hybridization | 9 | 0.0 |
Mutation/genetics | 5 | 0.0 |
Protein Isoforms/genetics | 3 | 1.0 |
Signal Transduction/genetics | 6 | 2.0 |
Transforming Growth Factor beta/*genetics | 2 | 2.0 |
Achondroplasia/genetics/metabolism | 2 | 100.0 |
Amino Acid Substitution | 10 | 0.0 |
Base Sequence | 43 | 0.0 |
Cell Line | 27 | 0.0 |
DNA, Complementary/genetics | 5 | 0.0 |
Dimerization | 4 | 0.0 |
Ligands | 6 | 0.0 |
Phosphorylation | 16 | 0.0 |
*Point Mutation | 26 | 2.0 |
Protein Structure, Quaternary | 2 | 1.0 |
Rats | 17 | 0.0 |
Recombinant Proteins/chemistry/genetics/metabolism | 3 | 0.0 |
Signal Transduction | 23 | 0.0 |
Thanatophoric Dysplasia/genetics/metabolism | 2 | 100.0 |
*Cell Transformation, Neoplastic | 4 | 0.0 |
Disease Progression | 7 | 0.0 |
Fibroblast Growth Factors/pharmacology | 3 | 4.0 |
*Alternative Splicing | 6 | 1.0 |
Receptors, Fibroblast Growth Factor/*genetics/metabolism | 8 | 36.0 |
Tumor Cells, Cultured | 21 | 0.0 |
Aged, 80 and over | 15 | 0.0 |
Disease-Free Survival | 2 | 0.0 |
Prognosis | 9 | 0.0 |
Bone Morphogenetic Proteins/genetics/metabolism | 2 | 16.0 |
Mice | 64 | 0.0 |
Mice, Nude | 3 | 0.0 |
Receptors, Fibroblast Growth Factor/metabolism | 3 | 6.0 |
Recombinant Proteins/metabolism | 7 | 0.0 |
Transcription Factors/genetics/*metabolism | 2 | 0.0 |
*Transforming Growth Factor beta | 2 | 1.0 |
Gene Expression Regulation | 9 | 0.0 |
Phosphotyrosine/metabolism | 5 | 1.0 |
Receptors, Fibroblast Growth Factor/genetics/*metabolism | 6 | 17.0 |
Signal Transduction/physiology | 2 | 0.0 |
3T3 Cells | 11 | 0.0 |
*Adaptor Proteins, Signal Transducing | 3 | 0.0 |
Amino Acid Sequence | 46 | 0.0 |
Cloning, Molecular | 15 | 0.0 |
DNA-Binding Proteins/*metabolism | 5 | 0.0 |
*Milk Proteins | 4 | 0.0 |
Molecular Sequence Data | 63 | 0.0 |
Mutagenesis, Site-Directed | 7 | 0.0 |
Trans-Activators/*metabolism | 5 | 0.0 |
Transfection | 15 | 0.0 |
Child | 32 | 0.0 |
Cohort Studies | 4 | 0.0 |
Heterozygote | 11 | 0.0 |
Models, Molecular | 2 | 0.0 |
Mutation/*genetics | 11 | 0.0 |
Prospective Studies | 3 | 0.0 |
Protein Structure, Tertiary | 4 | 0.0 |
Receptor Protein-Tyrosine Kinases/chemistry/*genetics | 2 | 11.0 |
Receptors, Fibroblast Growth Factor/chemistry/*genetics | 6 | 46.0 |
Alternative Splicing | 6 | 0.0 |
Blotting, Western | 11 | 0.0 |
Cell Division | 18 | 0.0 |
Cell Membrane/metabolism | 6 | 0.0 |
DNA, Complementary/metabolism | 5 | 0.0 |
DNA-Binding Proteins/metabolism | 5 | 0.0 |
Dose-Response Relationship, Drug | 3 | 0.0 |
Enzyme Activation | 7 | 0.0 |
Enzyme Inhibitors/pharmacology | 3 | 0.0 |
MAP Kinase Signaling System | 3 | 1.0 |
Precipitin Tests | 5 | 0.0 |
Protein Isoforms | 5 | 0.0 |
RNA/metabolism | 4 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 22 | 0.0 |
Trans-Activators/metabolism | 5 | 0.0 |
Transcription, Genetic | 4 | 0.0 |
Cattle | 4 | 0.0 |
DNA Primers | 15 | 0.0 |
Growth Plate/*metabolism | 2 | 50.0 |
Adolescent | 17 | 0.0 |
Tissue Distribution | 4 | 0.0 |
Facies | 2 | 7.0 |
*Mutation | 37 | 0.0 |
Syndrome | 16 | 0.0 |
Neoplasm Staging | 7 | 0.0 |
Polymerase Chain Reaction | 40 | 0.0 |
Sequence Analysis, DNA | 10 | 0.0 |
Thanatophoric Dysplasia/*genetics | 10 | 90.0 |
Craniosynostoses/genetics | 5 | 55.0 |
*Gene Expression | 3 | 0.0 |
Gestational Age | 12 | 1.0 |
RNA, Messenger/analysis | 6 | 0.0 |
Skull/*embryology | 3 | 37.0 |
*Mutation, Missense | 8 | 1.0 |
Genotype | 10 | 0.0 |
Mice, Inbred C57BL | 7 | 0.0 |
Chromosomes, Human, Pair 14/*genetics | 6 | 6.0 |
Chromosomes, Human, Pair 4/*genetics | 9 | 10.0 |
Multiple Myeloma/*genetics/pathology | 5 | 26.0 |
Protein-Tyrosine Kinase/genetics/metabolism | 3 | 4.0 |
RNA, Messenger/biosynthesis/genetics | 2 | 0.0 |
RNA, Neoplasm/biosynthesis/genetics | 2 | 3.0 |
*Signal Transduction | 3 | 0.0 |
*Translocation, Genetic | 22 | 2.0 |
*Chromosomes, Human, Pair 4 | 14 | 6.0 |
DNA-Binding Proteins/*genetics | 2 | 0.0 |
Oncogene Proteins, Fusion/*genetics | 3 | 1.0 |
Repressor Proteins/*genetics | 2 | 0.0 |
CHO Cells | 2 | 0.0 |
Cells, Cultured | 8 | 0.0 |
Exons | 13 | 0.0 |
Glycosylation | 3 | 0.0 |
Hamsters | 2 | 0.0 |
Models, Biological | 5 | 0.0 |
Protein Binding | 9 | 0.0 |
Receptors, Fibroblast Growth Factor/*chemistry/genetics/*metabolism | 2 | 66.0 |
Cell Differentiation/*physiology | 3 | 1.0 |
Cell Division/physiology | 5 | 0.0 |
Chondrocytes/*cytology | 2 | 12.0 |
Chromatography, High Pressure Liquid | 2 | 0.0 |
Cell Line, Transformed | 5 | 0.0 |
Chromosomes, Human, Pair 11 | 2 | 0.0 |
Chromosomes, Human, Pair 16 | 2 | 1.0 |
Chromosomes, Human, Pair 4 | 9 | 7.0 |
Immunoglobulins/genetics | 3 | 7.0 |
Models, Genetic | 8 | 0.0 |
Multiple Myeloma/*genetics | 15 | 35.0 |
Embryonic and Fetal Development | 3 | 0.0 |
Osteogenesis | 3 | 12.0 |
Receptor Protein-Tyrosine Kinases/*metabolism | 3 | 1.0 |
Cytoplasm/metabolism | 2 | 0.0 |
Genes, Reporter | 2 | 0.0 |
Microscopy, Fluorescence | 4 | 0.0 |
Nuclear Proteins/metabolism | 2 | 0.0 |
Plasmids/metabolism | 2 | 0.0 |
Promoter Regions (Genetics) | 5 | 0.0 |
Bone Diseases, Developmental/*genetics/radiography | 2 | 40.0 |
Gene Expression Regulation, Developmental | 6 | 0.0 |
Chromosomes, Human, Pair 14 | 3 | 1.0 |
Bladder Neoplasms/*genetics | 3 | 3.0 |
Bone Diseases, Developmental/genetics | 2 | 18.0 |
Receptors, Fibroblast Growth Factor/*physiology | 3 | 33.0 |
Cell Differentiation/physiology | 3 | 0.0 |
Fibroblast Growth Factor 1 | 2 | 7.0 |
Arginine/*genetics | 3 | 5.0 |
Craniosynostoses/*genetics | 13 | 36.0 |
Gene Expression | 18 | 0.0 |
Genes, Dominant/genetics | 2 | 1.0 |
Guanine | 2 | 2.0 |
Chromosome Mapping | 7 | 0.0 |
*Chromosomes, Human, Pair 14 | 8 | 4.0 |
Receptors, Fibroblast Growth Factor/chemistry/*genetics/metabolism | 3 | 60.0 |
Amino Acid Substitution/genetics | 2 | 0.0 |
Chondrocytes/pathology | 2 | 50.0 |
Disease Models, Animal | 6 | 0.0 |
Mice, Mutant Strains | 3 | 0.0 |
Genetic Markers | 8 | 0.0 |
Recurrence | 2 | 0.0 |
Craniofacial Dysostosis/genetics | 2 | 28.0 |
Neoplasm Proteins/genetics/metabolism | 2 | 1.0 |
Receptors, Fibroblast Growth Factor/*genetics/*metabolism | 11 | 64.0 |
Transcription Factors/genetics/metabolism | 2 | 0.0 |
Bladder Neoplasms/*genetics/pathology | 3 | 7.0 |
Oncogene Proteins, Fusion/genetics | 3 | 3.0 |
Conserved Sequence | 5 | 0.0 |
Receptor Protein-Tyrosine Kinases/*genetics | 7 | 1.0 |
Bone and Bones/radiography | 2 | 14.0 |
Reproducibility of Results | 3 | 0.0 |
1-Phosphatidylinositol 3-Kinase/*metabolism | 2 | 0.0 |
COS Cells | 6 | 0.0 |
Cercopithecus aethiops | 3 | 0.0 |
Mitogen-Activated Protein Kinase 1/metabolism | 2 | 0.0 |
Mitogen-Activated Protein Kinase 3 | 3 | 0.0 |
Mitogen-Activated Protein Kinases/metabolism | 4 | 0.0 |
Protein-Tyrosine Kinase/metabolism | 2 | 0.0 |
Cell Transformation, Neoplastic/*genetics | 2 | 1.0 |
Clone Cells/pathology | 2 | 3.0 |
Mice, Inbred BALB C | 2 | 0.0 |
*Oncogenes | 3 | 0.0 |
Osteochondrodysplasias/*genetics | 9 | 11.0 |
Sequence Alignment | 3 | 0.0 |
Sequence Homology, Amino Acid | 15 | 0.0 |
Acrocephalosyndactylia/*genetics | 4 | 18.0 |
Homeodomain Proteins/genetics | 3 | 1.0 |
DNA, Neoplasm/genetics | 5 | 0.0 |
Follow-Up Studies | 4 | 0.0 |
Polymerase Chain Reaction/methods | 2 | 0.0 |
Pregnancy | 13 | 0.0 |
*Prenatal Diagnosis | 6 | 2.0 |
Ultrasonography, Prenatal | 5 | 7.0 |
Abnormalities, Multiple/genetics | 2 | 2.0 |
Cysteine/*genetics | 3 | 11.0 |
*Down-Regulation | 3 | 0.0 |
Fibroblast Growth Factor 2/pharmacology | 2 | 0.0 |
Parathyroid Hormone-Related Protein | 3 | 3.0 |
Signal Transduction/*genetics | 2 | 1.0 |
*Trans-Activators | 4 | 0.0 |
Cell Line, Tumor | 6 | 0.0 |
Down-Regulation | 4 | 0.0 |
Protein Conformation | 2 | 0.0 |
Protein-Tyrosine Kinase/*metabolism | 2 | 0.0 |
*Chromosomes, Human, Pair 13 | 2 | 1.0 |
Immunoglobulins, Heavy-Chain/*genetics | 6 | 4.0 |
Genetic Screening | 2 | 0.0 |
Nuclear Proteins/genetics | 4 | 1.0 |
*Transcription Factors | 3 | 0.0 |
Multiple Myeloma/*genetics/metabolism/pathology | 2 | 40.0 |
Chondrocytes/cytology/*metabolism | 3 | 18.0 |
Receptors, Fibroblast Growth Factor/*biosynthesis/genetics | 3 | 27.0 |
Blotting, Southern | 5 | 0.0 |
Bone Marrow/pathology | 2 | 0.0 |
Immunoglobulin Switch Region/genetics | 2 | 66.0 |
Paraproteinemias/genetics | 3 | 100.0 |
Survival Rate | 3 | 0.0 |
Linkage (Genetics) | 4 | 0.0 |
*Gene Expression Regulation, Neoplastic | 7 | 0.0 |
Proteins/*genetics | 2 | 0.0 |
Receptor Protein-Tyrosine Kinases/genetics | 8 | 5.0 |
Blotting, Northern | 8 | 0.0 |
Germ-Line Mutation | 2 | 0.0 |
RNA, Messenger/analysis/genetics | 2 | 0.0 |
Apoptosis | 2 | 0.0 |
Chromosome Aberrations | 4 | 0.0 |
Craniosynostoses/*genetics/pathology | 2 | 33.0 |
DNA/genetics | 4 | 0.0 |
Microsatellite Repeats | 3 | 0.0 |
Diagnosis, Differential | 3 | 0.0 |
Pregnancy Trimester, Second | 2 | 0.0 |
Introns | 6 | 0.0 |
RNA Splicing | 4 | 0.0 |
*Fibroblast Growth Factors | 8 | 9.0 |
Alternative Splicing/*genetics | 2 | 1.0 |
Receptors, Fibroblast Growth Factor/biosynthesis/*genetics | 5 | 45.0 |
1-Phosphatidylinositol 3-Kinase/metabolism | 2 | 0.0 |
Myristic Acid | 2 | 8.0 |
PC12 Cells | 3 | 0.0 |
Protein-Tyrosine-Phosphatase/metabolism | 2 | 1.0 |
Growth Substances/pharmacology | 2 | 1.0 |
Protein-Tyrosine Kinase/genetics | 2 | 1.0 |
Skull/*abnormalities | 2 | 10.0 |
Mice, Transgenic | 15 | 0.0 |
Age Factors | 2 | 0.0 |
*Paternal Age | 2 | 50.0 |
Protein-Tyrosine Kinase/*genetics | 7 | 3.0 |
Alleles | 4 | 0.0 |
*Chromosomes, Human, Pair 11 | 3 | 0.0 |
Immunoglobulins/*genetics | 2 | 4.0 |
Sensitivity and Specificity | 2 | 0.0 |
Leukemia, Plasmacytic/*genetics | 2 | 50.0 |
*Apoptosis | 2 | 0.0 |
Cell Division/drug effects | 6 | 0.0 |
Chromosomes, Human, Pair 14/*genetics/ultrastructure | 2 | 33.0 |
Chromosomes, Human, Pair 4/*genetics/ultrastructure | 2 | 50.0 |
Protein Processing, Post-Translational | 2 | 0.0 |
Signal Transduction/*physiology | 2 | 0.0 |
Translocation, Genetic/*genetics | 4 | 1.0 |
DNA Mutational Analysis/*methods | 2 | 1.0 |
Bone Development | 4 | 14.0 |
Chondrocytes/cytology/metabolism | 5 | 41.0 |
Kinetics | 5 | 0.0 |
Gene Targeting | 4 | 1.0 |
Osteogenesis/*genetics | 2 | 20.0 |
Body Height | 2 | 1.0 |
Craniosynostoses/classification/*diagnosis/genetics | 2 | 100.0 |
*DNA Mutational Analysis | 3 | 1.0 |
*Polymerase Chain Reaction | 4 | 1.0 |
Binding, Competitive | 3 | 0.0 |
Chimeric Proteins/metabolism | 2 | 1.0 |
Receptor Protein-Tyrosine Kinases/genetics/metabolism | 5 | 8.0 |
Substrate Specificity | 3 | 0.0 |
Chondrocytes/*metabolism | 3 | 9.0 |
Growth Substances/*biosynthesis/genetics | 2 | 7.0 |
Osteochondrodysplasias/*metabolism | 2 | 100.0 |
*Bone Development | 2 | 14.0 |
Bone Morphogenetic Proteins/genetics | 3 | 9.0 |
Cartilage, Articular/embryology | 2 | 100.0 |
Collagen/genetics | 5 | 5.0 |
Genes, Homeobox | 2 | 2.0 |
Homeodomain Proteins/genetics/*physiology | 2 | 3.0 |
*Neoplasm Proteins | 2 | 0.0 |
Proteins/genetics | 3 | 0.0 |
Spine/*embryology | 2 | 100.0 |
Spleen/*embryology | 2 | 66.0 |
Receptor Protein-Tyrosine Kinases/genetics/*physiology | 2 | 7.0 |
Receptors, Fibroblast Growth Factor/genetics/*physiology | 2 | 22.0 |
Antibodies, Monoclonal/pharmacology | 2 | 0.0 |
Receptor, Parathyroid Hormone, Type 1 | 2 | 14.0 |
Receptors, Parathyroid Hormone/*genetics | 2 | 20.0 |
Fibroblast Growth Factors/*metabolism | 3 | 7.0 |
Mice, Knockout | 4 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 8 | 0.0 |
Species Specificity | 4 | 0.0 |
Age of Onset | 2 | 0.0 |
DNA Primers/genetics | 4 | 0.0 |
Carrier Proteins/*genetics | 2 | 0.0 |
*Gene Expression Regulation | 2 | 0.0 |
Genes, Immunoglobulin | 3 | 1.0 |
Immunoglobulins, Heavy-Chain/genetics | 2 | 1.0 |
In Situ Hybridization, Fluorescence/*methods | 2 | 2.0 |
Lysine/genetics | 2 | 5.0 |
Genes, Dominant | 7 | 0.0 |
Cattle Diseases/*genetics | 3 | 75.0 |
*Chromosome Mapping | 5 | 0.0 |
Dwarfism/genetics/*veterinary | 3 | 100.0 |
Osteochondrodysplasias/genetics/*veterinary | 2 | 100.0 |
Crosses, Genetic | 2 | 0.0 |
Mice, Inbred Strains | 3 | 0.0 |
Chromosome Disorders | 2 | 0.0 |
Chromosomes, Human, Pair 4/genetics | 3 | 4.0 |
Glycine/genetics | 2 | 2.0 |
Point Mutation/*genetics | 6 | 2.0 |
Spain | 2 | 0.0 |
Restriction Mapping | 3 | 0.0 |
Molecular Biology | 3 | 1.0 |
Treatment Outcome | 2 | 0.0 |
Amniocentesis | 2 | 2.0 |
Thanatophoric Dysplasia/*diagnosis/*genetics | 2 | 100.0 |
Acanthosis Nigricans/complications/*genetics | 2 | 100.0 |
Immunoblotting | 3 | 0.0 |
Skull/abnormalities | 2 | 14.0 |
China | 2 | 0.0 |
Homozygote | 6 | 0.0 |
Aneuploidy | 2 | 1.0 |
Gene Expression Regulation, Developmental/genetics | 2 | 2.0 |
Retrospective Studies | 3 | 0.0 |
*Carrier Proteins | 2 | 0.0 |
*Repressor Proteins | 2 | 0.0 |
Gene Frequency | 2 | 0.0 |
*Polymorphism, Single-Stranded Conformational | 2 | 1.0 |
Achondroplasia/genetics | 4 | 57.0 |
Variation (Genetics) | 3 | 0.0 |
Femur/abnormalities/radiography | 2 | 100.0 |
Skull/abnormalities/radiography | 2 | 66.0 |
Acrocephalosyndactylia/genetics | 2 | 15.0 |
Fibroblast Growth Factors/*biosynthesis/genetics | 2 | 20.0 |
Genetic Heterogeneity | 3 | 1.0 |
Transcription Factors/*genetics | 3 | 0.0 |
Abnormalities, Multiple/*genetics | 3 | 0.0 |
Growth Disorders/*genetics | 3 | 5.0 |
Reference Values | 3 | 0.0 |
Binding Sites | 3 | 0.0 |
CpG Islands | 2 | 0.0 |
Fibroblast Growth Factors/genetics | 6 | 15.0 |
Proto-Oncogene Proteins/genetics | 3 | 0.0 |
Heterozygote Detection | 2 | 0.0 |
Diseases in Twins | 2 | 4.0 |
Chromosomes, Human, Pair 14/genetics | 3 | 3.0 |
*Chromosomes, Human, Pair 7 | 2 | 0.0 |
Software | 2 | 0.0 |
Multigene Family | 2 | 0.0 |
DNA Probes | 2 | 0.0 |
Oncogenes/genetics | 2 | 2.0 |
Cartilage/physiology | 2 | 33.0 |
Structure-Activity Relationship | 2 | 0.0 |
Cell Compartmentation | 2 | 0.0 |
Fluorescent Antibody Technique, Indirect | 3 | 0.0 |
Fibroblast Growth Factor 1/pharmacology | 2 | 8.0 |
Sequence Homology, Nucleic Acid | 5 | 0.0 |
Ca(2+)-Calmodulin Dependent Protein Kinase/metabolism | 2 | 0.0 |
Japan | 3 | 0.0 |
Fibroblast Growth Factors | 2 | 14.0 |
Craniofacial Dysostosis/complications/*genetics | 2 | 100.0 |
Brain/pathology | 2 | 0.0 |
RNA, Messenger/genetics | 2 | 0.0 |
Osteochondrodysplasias/*genetics/metabolism | 2 | 66.0 |
Hydrogen Bonding | 2 | 1.0 |
Receptors, Fibroblast Growth Factor/*antagonists & inhibitors | 2 | 50.0 |
Genes, p53/*genetics | 2 | 0.0 |
Body Height/*genetics | 2 | 7.0 |
Cell Differentiation/genetics | 3 | 1.0 |
DNA/biosynthesis | 2 | 0.0 |
DNA-Binding Proteins/genetics/*metabolism | 2 | 0.0 |
High Mobility Group Proteins/genetics | 2 | 5.0 |
Oligonucleotide Array Sequence Analysis/*methods | 2 | 1.0 |
Organ Specificity | 2 | 0.0 |
Fibroblast Growth Factor 2/metabolism | 2 | 2.0 |
Pregnancy Trimester, Third | 2 | 1.0 |
Cyclins/genetics/*metabolism | 2 | 2.0 |
Protein-Tyrosine Kinase/*genetics/*metabolism | 3 | 14.0 |
Nucleic Acid Hybridization | 2 | 0.0 |
Immunoenzyme Techniques | 2 | 0.0 |
*Chromosome Aberrations | 2 | 0.0 |
MAP Kinase Signaling System/drug effects | 2 | 2.0 |
Signal Transduction/drug effects | 2 | 0.0 |
Cysteine Endopeptidases/metabolism | 2 | 0.0 |
Multienzyme Complexes/metabolism | 2 | 1.0 |
Proteasome Endopeptidase Complex | 2 | 0.0 |
Cell Division/genetics | 2 | 0.0 |
Magnetic Resonance Imaging | 2 | 0.0 |
Parathyroid Hormone-Related Protein/*metabolism | 2 | 66.0 |
Bone Marrow/chemistry | 2 | 6.0 |
